Awardee OrganizationALBERT EINSTEIN COLLEGE OF MEDICINE
Description
Abstract Text
Very little is known about human genes that can confer increased
susceptibility or resistance to environmental carcinogens. Most exciting
knowledge has been obtained from studies based on the much extensive
experimental data obtained in laboratory animals. The studies proposed
here are aimed at elucidating the genetic basis of the marked differences
in the incidence of T-cell lymphoma among mice of certain inbred strains
following percutaneous application of 3-methylcholanthrene (MA). The
primary goal is to build upon our previous data indicating that a single
dominant gene is the major determinant of relative resistance to MA
lymphomagenesis and to map this gene. The goal will be studied first in an
analysis of DNA from mice of a new set of recombinant inbred (RI) mice,
SWXD1, by searching for correlations between MA lymphoma incidence and
other genetic polymorphisms, primarily restriction fragment length
polymorphisms detected by the use of probes for endogenous murine leukemia
viruses, that are widely distributed among the chromosomes of mice.
Similarly, this same approach will be applied to the analysis of DNAs from
individual mice of a large backcross population segregating for the
presence or absence of the MA resistance gene and observed for lymphoma
after MA treatment. Another goal stems from experiments suggesting that
this same resistance gene may play a role in resistance to lymphomagenesis
by fractionated doses of whole body irradiation; this possibility will also
be studied in the SWXD1 strains by comparing the lymphoma incidences in
each strain after treatment with MCA vs. irradiation. A third goal
involves the exploration of the genetic basis for the marked, genetically
recessive hypersensitivity of mice of the RF/J strain to lymphomagenesis by
a low total dose (200 rad) of fractionated irradiation, by comparison with
other strains that are highly susceptible at higher doses but resistant at
the low dose. We will pursue any suggestions of biological mechanisms that
might be responsible for these differences in lymphoma resistance by
attempting to correlate them with the distributions of the resistance
genes.
No Sub Projects information available for 5R01CA052621-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA052621-03
Patents
No Patents information available for 5R01CA052621-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA052621-03
Clinical Studies
No Clinical Studies information available for 5R01CA052621-03
News and More
Related News Releases
No news release information available for 5R01CA052621-03
History
No Historical information available for 5R01CA052621-03
Similar Projects
No Similar Projects information available for 5R01CA052621-03